Fosun Pharma: Controlled subsidiary receives approval from the US FDA for drug clinical trials.

Fosun Pharmaceutical announced that its subsidiary, Shanghai Jinji Health Technology Co., Ltd., has received approval from the US FDA to conduct clinical trials for LBP-ShC4. Jinji Health plans to begin Phase I clinical trials for LBP-ShC4 once the conditions are met. LBP-ShC4 is a live biological therapy product developed independently by the group, intended for the treatment of male pattern baldness. As of April 2025, the group has invested approximately RMB 17 million in research and development for LBP-ShC4. As of the date of this announcement, there is currently no live biological therapy product approved for the treatment of male pattern baldness on the market globally.